echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > How's the research and development going? How far is the new crown special effects drug coming out?

    How's the research and development going? How far is the new crown special effects drug coming out?

    • Last Update: 2020-11-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    , Beijing, July 6 (Xinhua Zhang Ying) The new crown epidemic is still spreading around the world. In addition to vaccines, people are also counting on special-effects drugs. At present, more and more candidate drugs have entered the field of scientific research, a large number of clinical trials are being carried out around the world, but the real new coronary special effects drugs have not yet appeared.
    so, what is the progress of the research and development of the new crown special effects drug? Where's the break? How long will it take for real special effects drugs to come out?to develop specific antiviral drugs, the first step is to screen and design drug targets based on the key mechanisms of the new coronavirus invading human cells, self-replication and disease.
    Li Wenhui, a researcher at the Beijing Institute of Life Sciences, recently told Xinhua that new crown drug targets are known to be divided into two categories, one targeting the new coronavirus itself and the other targeting the host, the human body. Targets for viruses can also be subdivided, one for virus invasion phases, such as prickly proteins that help viruses invade cells, whose bind binding domain (RBD) is a key target, and the other for virus replication phases, where the main protease and "RNA-dependent RNA polymerase (RdRp)" are considered two more promising targets.
    The main protease is like a "magic shear", there are at least 11 cutting points on the new coronavirus replication enzyme peptides, only when these bits are correctly cut, these virus replication-related "parts" can be successfully assembled into a replication transcription machine, starting the replication of the virus. RdRp, on the other way, is like the core "engine" of viral RNA (RNA) synthesis, with the virus cleverly using other cofactors to assemble an efficient RNA synthesis machine to replicate itself.
    have so far successfully observed the structure of several new coronavirus targets. Relevant research has laid a solid foundation for the research and development of new crown drugs.
    first reported the three-dimensional structure of the hedgehog protein at the atomic scale in February. In March, teams at Shanghai University of Science and Technology and Tsinghua University analyzed the three-dimensional spatial structure of the near-atomic resolution of the RdRp-nsp7-nsp8 complex, the core "engine" of the transcriptional replication machine. Shanghai University of Science and Technology and
    Shanghai Institute of Pharmaceutical Research and other institutions in April reported a main protease strong inhibitor N3, and the first analysis of the "main protease-N3" high-resolution complex structure.
    more complex to target drugs that target the human body because of the variety of symptoms of neo-coronavirus infection, which affects multiple organs. In terms of treatment, more of these targets are still being explored, some of which target the immune system.According to experts, in the research of new crown drugs basically cover the common drug types, in small molecules targeted drugs, bio-molecular drugs and other directions have made progress, the future may also appear stem cell therapy, gene therapy and other candidate therapies.
    small molecule drug development, several teams reported new findings of candidate compounds targeting the main protease, which they believe have the potential to develop into new crown drugs. Researchers at the University of Luebeck in Germany developed α-ketonamide-like antiviral compounds targeting the main protease after the SARS outbreak, and in May this year published their "improved" version of α-ketamine 13b cellular experimental data. Australian researchers have confirmed through computer simulations that it can effectively prevent the replication of new coronavirus.
    June 19 in the American journal Science presents two compounds, 11a and 11b, found by Chinese researchers targeting the main protease. The team not only analyzed the patterns of interaction between the two compounds and the new coronavirus main protease, but also revealed the molecular mechanisms by which they inhibited the main protease.
    the development of bio-molecular drugs, teams around the world have reported monoclonal antibodies against the new coronavirus.
    Microbiology Research Institute and Shanghai Junshi Biopharmaceutical Technology Co., Ltd. and other units jointly developed the reorganization of the whole human source anti-neo-coronavirus monoclonal antibody injection was recently approved for clinical trials, is expected to be used in the near future for the prevention and treatment of new crown infection.
    the drug candidate based on monoantion CB6 isolated from patients recovering from the new crown by a Chinese research team. In animal experiments using rhesus monkeys, CB6 showed a high degree of overlap with hedgehog RBD binding points and host cells, and was more "affinity" than host cells, and had clinical prospects, the British journal Nature reported online in May."new use of old drugs" is also one of the main research and development strategies of new crown drugs. If effective drugs for new coronavirus infection can be found from existing drugs, they can bypass the stages of pharmacological research, animal experiments, etc. and go directly to clinical trials.
    common corticosteroid hormone dexamisone has been shown to reduce the risk of death in patients at risk of re-coronary disease. In clinical trials, a team led by a team at the University of Oxford in the UK used dexamison in more than 2,000 new patients with severe conditions, a drug that reduced the risk of death in patients who needed a ventilator by 35 per cent and oxygen-absorbing patients by 20 per cent. The World Health Organization has called for an increase in the production of the drug.
    drugs such as redsivir, Fabiravir, and tozhu monoantigen also showed some clinical effects in different groups of new crown patients, although the clinical effects of hydroxychloroquine, which had been hoped for, were not as good as expected.
    What effect do some old drugs have on known targets and known mechanisms, and now there are some new clinical trial results," Ding Sheng, director of the Global Center for Health Drug Research and Development and
    director of Tsinghua University School of Pharmacy, told Xinhua.
    Dingsheng also stressed that the "old drug" is not a drug developed for the new coronavirus after all, researchers still have to use proven targets to develop new coronary drugs. There has been a lot of accumulation in basic research for the development of new crown drugs, but there is no shortcut to the development of new drugs, and developing a new drug can take up to 10 years and hundreds of millions of dollars in funding to eventually be approved. Drug research and development for the new coronavirus is supported by specific scientific laws and strict logic, which cannot be achieved overnight.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.